The global monoclonal antibodies market size reached US$ 207.4 Billion in 2022. Looking forward, IMARC Group expects the market to reach US$ 307.8 Billion by 2028, exhibiting a growth rate (CAGR) of 6.9% during 2023-2028.
Monoclonal antibodies (mAbs) are laboratory-produced proteins used to serve as substitute antibodies that can enhance, modify, restore, and mimic the attack of the immune system on unwanted cells. They are utilized for detecting and targetting cancer cells for destruction by enhancing the immune system. They are also employed to block the connection between a cancer cell and proteins that promote cell growth. In addition, they prevent the formation of proteins for enabling immune system cells to work efficiently against cancer cells. Besides this, mAbs transport the radiation treatment directly to cancer cells and minimize the effect of radiation on healthy cells.
Monoclonal Antibodies Market Trends:
- At present, the growing prevalence of chronic diseases, such as cancer, heart disease, stroke, diabetes, and arthritis, represents one of the key factors driving the market. Besides this, leading manufacturers are extensively investing in research and development (R&D) activities to introduce enhanced mAb drugs for treating neurodegenerative diseases, such as Alzheimer's, Huntington's, Parkinson's, and Lewy body diseases. They are also focusing on various marketing strategies to expand their customer base, which is contributing to the growth of the market. In addition, the increasing demand for humanized mAbs to treat various antigens, such as cancer cells, immunosuppression, and immunomodulatory molecules, are offering lucrative growth opportunities to industry investors. Apart from this, there is a rise in the demand for cost-efficient biosimilar mAbs to treat cancer across the globe. This, along with the burgeoning healthcare industry, is propelling the growth of the market. Moreover, technological advancements in various genetic platforms, such as next-generation sequencing, is offering a positive market outlook. Additionally, there is an increase in the employment of advanced genetic engineering technology in mAbs production around the world. This, coupled with the rising awareness among the masses about the benefits of mAb therapy, is bolstering the market growth.
Key Market Segmentation:
- IMARC Group provides an analysis of the key trends in each sub-segment of the global monoclonal antibodies market report, along with forecasts at the global, regional and country level from 2023-2028. Our report has categorized the market based on production method, source, indication and end use.
Breakup by Production Method:
Breakup by Source:
Breakup by Indication:
- Autoimmune Diseases
- Inflammatory Diseases
- Infectious Diseases
Breakup by End Use:
- Research Institutes
Breakup by Region:
- North America
- United States
- South Korea
- United Kingdom
- Latin America
- Middle East and Africa
- The competitive landscape of the industry has also been examined along with the profiles of the key players being AbbVie Inc., Amgen Inc., Biogen Inc., F. Hoffmann-La Roche AG, GSK plc, Johnson & Johnson, Merck KGaA, Novartis AG, Novo Nordisk A/S, Pfizer Inc., Sanofi S.A. and Thermo Fisher Scientific Inc.
Key Questions Answered in This Report:
- 1. What was the size of the global monoclonal antibodies market in 2022?
- 2. What is the expected growth rate of the global monoclonal antibodies market during 2023-2028?
- 3. What are the key factors driving the global monoclonal antibodies market?
- 4. What has been the impact of COVID-19 on the global monoclonal antibodies market?
- 5. What is the breakup of the global monoclonal antibodies market based on the production method?
- 6. What is the breakup of the global monoclonal antibodies market based on the source?
- 7. What is the breakup of the global monoclonal antibodies market based on the indication?
- 8. What is the breakup of the global monoclonal antibodies market based on the end use?
- 9. What are the key regions in the global monoclonal antibodies market?
- 10. Who are the key players/companies in the global monoclonal antibodies market?